Dtsch Med Wochenschr 2021; 146(18): 1218-1225
DOI: 10.1055/a-1529-4521

Typ-2-Diabetes-mellitus und Krebsrisiko

Type-2-diabetes and cancer risk
Hans Scherübl

Typ-2-Diabetes-mellitus-Patienten sterben heute am häufigsten an Krebs. In Dickdarm, Bauchspeicheldrüse, Gallenblase, Leber, Magen und vielen weiteren Geweben können sich T2D-assoziierte Malignomen bilden. Weitere Faktoren, wie z. B. Tabakkonsum, Bewegungsmangel und Übergewicht, erhöhen das Risiko. Menschen mit Typ-2-Diabetes sollten deshalb frühzeitig und regelmäßig zur Teilnahme an etablierten Krebsfrüherkennungsmaßnahmen eingeladen werden.


Type-2-diabetes (T2D) increases the risk for several cancers and cancer has become the major cause of death of T2D-patients. T2D is causally associated with colorectal, pancreatic, gallbladder, biliary, hepatocellular, gastric, esophageal, oral, breast, endometrial, ovary, kidney and thyroid cancers as well as leukemias. When T2D goes along with tobacco smoking, alcohol use, physical inactivity, excess body weight, poor diet, familial risk or certain chronic infections, the cumulative cancer risk rises, and T2D-patients often suffer from cancer disease at younger age. T2D-patients should be encouraged to join cancer screening programmes even at younger age than the average non-diabetic population.

Publication History

Article published online:
14 September 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Literatur

  • 1 Dagenais GR, Leong DP, Rangarajan S. et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2020; 395: 785-794
  • 2 Pearson-Stuttard J, Bennett J, Cheng YJ. et al. Trends in pre-dominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol 2021; 9: 165-173
  • 3 Mikaeel RR, Symonds EL, Kimber J. et al. Young-onset colorectal cancer is associated with a personal history of type 2 diabetes. Asia Pac J Clin Oncol 2021; 17: 131-138
  • 4 Lu S, Wang A, Miao S. et al. Association between type 2 diabetes and cancer incidence in China: data in hospitalized patients from 2006 to 2013. Ann Transl Med 2020; 8: 176
  • 5 Sung H, Siegel RL, Rosenberg PS. et al. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019; 4: e137-e147
  • 6 Rustgi VK, Li Y, Gupta K. et al Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology 2021; S0016-5085(21)00529-1
  • 7 Gallagher EJ, LeRoith D. Hyperinsulinaemia in cancer. Nat Rev Cancer 2020; 20: 629-644
  • 8 National Foundation for Cancer Research (NFCR). Diabetes and Cancer: What’s the Link?. Im Internet (Stand: 25.07.2021): https://www.nfcr.org/blog/diabetes-and-cancer-whats-the-link/
  • 9 Lee SC, Chan JC. Evidence for DNA damage as a biological link between diabetes and cancer. Chin Med J (Engl) 2015; 128: 1543-1548
  • 10 von Wagner C, Cadar D, Hackett RA. et al. Type 2 diabetes and colorectal cancer screening: Findings from the English Longitudinal Study of Ageing. J Med Screen 2020; 27: 25-30
  • 11 Ali Khan U, Fallah M, Sundquist K. et al. Risk of colorectal cancer in patients with diabetes mellitus: A Swedish nationwide cohort study. PLoS Med 2020; 17: e1003431
  • 12 Li Z, Zheng X, Nickel K. et al. Diabetes and risk of early-onset colorectal cancer. Cancer Res 2020; 16 (80) 2351
  • 13 Baecker A, Liu X, La Vecchia C. et al. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev 2018; 27: 205-212
  • 14 Simon TG, King LY, Chong DQ. et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology 2018; 67: 1797-1806
  • 15 Boyle P, Boniol M, Koechlin A. et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 2012; 107: 1608-1617
  • 16 Chen X, Wang Q, Zhang Y. et al. Physical Activity and Risk of Breast Cancer: A Meta-Analysis of 38 Cohort Studies in 45 Study Reports. Value Health 2019; 22: 104-128
  • 17 Graff RE, Sanchez A, Tobias DK. et al. Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies. Diabetes Care 2018; 41: 1432-1437
  • 18 Wang S, Lo Galbo MD, Blair C. et al. Diabetes and kidney cancer risk among post-menopausal women: The Iowa women's health study. Maturitas 2021; 143: 190-196
  • 19 GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2019; 4: 934-947
  • 20 Yuan C, Babic A, Khalaf N. et al. Diabetes, Weight Change, and Pancreatic Cancer Risk. JAMA Oncol 2020; 6 (10) e202948
  • 21 Duconseil P, Adham M, Sauvanet A. et al. Fukuoka-Negative Branch-Duct IPMNs: When to Worry? A Study from the French Surgical Association (AFC). Ann Surg Oncol 2018; 25: 1017-1025
  • 22 Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. Gastroenterology 2020; 159: 358-362
  • 23 Heredia-Soto V, Rodríguez-Salas N, Feliu J. Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?. Cancers (Basel) 2021; 13: 1986
  • 24 Bergquist JR, Leiting JL, Habermann EB. et al. Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surgery 2019; 166: 547-555
  • 25 Jun JK, Choi KS, Lee HY. et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology 2017; 152: 1319-1328